Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly & Co. LLY shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%.

Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry November 05, 2024 — 10:00 am EST Written by Benzinga Insights for Benzinga -> ...

• LLY stock fell 17.0% from a high of $374.76 on 4 December 2022 to $311.22 on 28 February 2023, vs. a peak-to-trough decline of 25.4% for the S&P 500 • The stock fully recovered to its pre ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (LLY-1.06%) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity) rose dramatically to reach $6.2 billion, up year over year from $2.3 billion.

The stock's fall snapped a four-day winning streak.